Report Overview

The global Fanconi Anemia Treatment market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Fanconi anemia is an autosomal recessive disease which identify by defective haemopoiesis, congenital abnormalities and patients are high risk on developing solid tumors and acute myeloid leukemia. It is a rare disease which passed through the families (inherited) that affects the bone marrow. Patients suffering from fanconi anemia show the symptoms like; shortness of breath, recurrent nose bleeding, fatigue, recurrent viral infection and cold, short stature and poor growth and others

A newer medicine, eltrombopag, to treat anemia and low blood cell counts in patients who have Fanconi anemia. The FDA approved eltrombopag for severe aplastic anemia



Market Drivers

Rising prevalence of the blood disorders worldwide and emerging markets are the factors responsible for the growth of this market

Growing cases of blood disorders drives the fanconi anemia treatment market. Due to gene mutation increases the risk of evolving blood disorders also boost up the fanconi anemia treatment market growth. In addition, the availability of the treatment is also witnessing the growth of this market. Furthermore, availability of cost effective drugs can be considered one of the progressive factors for the growth of this market. Moreover, various treatment present in the market also witnessing the growth of fanconi anemia treatment market. Cost effective treatment contributes to the growth of global fanconi anemia treatment market